Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

U.K. commits a further $375M to 100,000 Genomes Project

The United Kingdom has committed a further $375 million to its massive sequencing initiative, the 100,000 Genomes Project. Government officials are making the extra cash available to finance the introduction of whole-genome sequencing into the National Health Service.

MediSapiens applies bioinformatics to find ideal leukemia treatment regimens

MediSapiens has provided Helsinki University Central Hospital with a bioinformatics platform to support the personalization of leukemia care. The system is designed to help physicians find the best treatment for each patient--and funnel data gained in the field back to support drug R&D initiatives.

With PhIII trial coming up, Infinity strikes risk-based monitoring deal with Medidata

Infinity Pharmaceuticals has added risk-based monitoring (RBM) to the suite of eClinical tools it sources from Medidata. The expansion of the 10-year relationship gives Infinity access to RBM technology at a time when it is gearing up for a Phase III cancer trial.

Heptares lands $410M deal with Teva to apply structure-based design to migraine targets

Heptares has bagged another R&D collaboration on the strength of its structure-based approach to drug discovery. Teva is the latest big-name drugmaker to turn to Heptares for help, handing over $10 million upfront and committing to up to $400 million more in a bid to gain migraine assets.

BGI slams brakes on Revolocity rollout, lays off staff in business rethink

BGI has slammed the brakes on the rollout of the population-scale sequencing system that was set to offer an alternative to Illumina's HiSeq X platform, GenomeWeb reports. The setback is part of a wider rejig at BGI's Complete Genomics subsidiary, which is firing a "substantial" number of staff, changing CEOs and retooling to become a BGISEQ-500-focused R&D shop.

Pfizer-Allergan merger raises questions about future of NuMedii deal

Speculation about the fallout from Pfizer and Allergan's $160 billion megamerger has begun.

FDA gives scientists freedom to tweet in long-awaited social media policy

The regulator, which has faced criticism in the past over its failure to establish a policy, set out its position in a 12-page document.

Amazon shares landmark cancer genome data sets on cloud platform

Amazon has made The Cancer Genome Atlas and The International Cancer Genome Consortium PanCancer data sets freely available through its cloud platform. The addition of the data sets continues Amazon's push to differentiate its cloud offering through the availability of data.

Illumina to make 5,000-genome autism database available through BaseSpace

Illumina is to make a 5,000-genome autism database available through BaseSpace. The deal will enable researchers to analyze the genomes of people with autism and their families using tools built into Illumina's cloud computing platform.

Molecular Health raises $27M to advance data-crunching tech

Molecular Health has raised $27 million to drive adoption of its data-crunching technology, which includes a tool aimed at drug developers. The investment moves the sum raised by Molecular Health to date beyond the $100 million mark.